# Artivila

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artivila

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.artivila.com
- Latest round: Series A (Jun 25, 2026)
- Investors on record: 4

## About

Based in Shenzhen, China and founded in 2018, Artivila Biopharma Co., Ltd., dba Artivila, is a biotechnology company that engages in the research and development of drugs for neuro-degenerative diseases, cancers and autoimmune diseases through AI powered drug discovery engine. The founder of the company, Dr. Mike Zhu, received a doctor degree from University of Fribourg and was the principal Investigator at Celgene, the principal Investigator at Avila Therapeutics and the principal Scientist at Pfizer. Dr. Mike Zhu has more than 19 years of drug discovery experience, especially in the fields of data analysis, AI / ML approach, drug design, cheminformatics and computational chemistry. The co-founder of the company, Dr. David Niu, finished a doctor degree from New York University and was the vice president at Silicon Therapeutics and the director of Chemistry at Celgene. Dr. David Niu participated in over 10 projects that advanced into clinical stages, which includes the 3rd generation EGFR inhibitor, an HCV drug, and several clinical candidates in Celgene. In June 2026, Artivila closed Series A funding led by Green Pine Capital Partners, with participation from Junyi Investment, and other investors.

The company's main business is an AI-driven R&D platform eLead, it enables developers to targets search, targets validation, lead discovery and optimization, candidates selection, IND enabling and clinical trials. Besides, the company focuses on the development of drugs for neurodegenerative diseases, autoimmune diseases and oncology.

The company generates revenue from providing AI-driven R&D platform for its clients.

## Funding rounds

- Series A, Jun 25, 2026 — Green Pine Capital Partners, Junyi Investment
- Angel, Nov 4, 2019 — AnlongMed Investment, Shenzhen Qianhai Bopu Asset Management Limited

## Investors

- AnlongMed Investment — Angel
- Shenzhen Qianhai Bopu Asset Management Limited — Angel
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- Junyi Investment — Series A